Compound ID | 2861
ClyQ
Class: Bacteriophage and/or bacteriophage-derived product
| Spectrum of activity: | Gram-positive |
| Details of activity: | Active against methicillin-resistant and -susceptible Staphylococcus aureus |
| Description: | Constructed chimeric lysin by combining phage lysin LysGH15 from Staphylococcus aureus and phage lysin PlyV12 cell wall-binding domain from Enterococcus faecalis; shows synergistic effect with mupirocin in removing methicillin-resistant Staphylococcus aureus in skin infection model |
| Institute where first reported: | Key Laboratory of Preventive Veterinary Medicine in Hubei Province, The Cooperative Innovation Center for Sustainable Pig Production, Wuhan, China; Huazhong Agricultural University |
| Year first mentioned: | 2023 |
| Development status: | Experimental |
| External links: | |
| Citation: | https://journals.asm.org/doi/10.1128/spectrum.05050-22 |
| Patent: | CN114736894A |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.